Updated: Bayer cuts PhII orphan drug as it ups R&D spending, questions swirl around new CEO’s next moves
Bayer has shuttered a Phase II program that the EMA had designated an orphan drug “for scientific reasons,” the German conglomerate disclosed in its half-year report.
The cut comes as Bayer reports pharma earnings that are below the prior year — despite “stable sales” — due to “higher R&D investments in cell and gene therapy and chemoproteomics technologies, as well as in projects in advanced clinical development.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.